Mylan (MYL) Gains on Generic Concerta Approval
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Mylan (NASDAQ: MYL) is active today after AB-rated approval on generic Concerta (methylphenidate hydrochloride) per the FDA website 10/21.
RBC analyst Randall Stanicky notes this approval follows last week’s announcement by FDA that it would pursue removal of BX-rated versions sold by MNK and LCI (Kudco) which would effectively leave TEVA alone in the market (acquired via AGN).
However, per the firm's back and forth with MYL today, it is unclear when the company will be able to launch as settlement terms with JNJ are undisclosed. Per JNJ's 10-k, it appears settlement was entered into around October 2015.
For TEVA (NASDQ: TEVA), they believe generic Concerta is ~$0.25 to EPS (4%) and an important product but one that we fully expect to see additional generic competition on and thus not a growth driver. TEVA may see some incremental upside for a short period of time given the potential for (we think likely) removal of BX competitors per FDA last week who collectively had ~15% share combined (TEVA ~78%) - 11% (MNK) and 4% (LCI) share.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citron Research Negative on TransDigm Group (TDG) amid Trump Era; Calls Valeant of Aerospace
- BTIG Says Synergy's (SGYP) Trulance Low Incidence of Side Effects the Key Differentiator
- UPDATE: SunTrust Robinson Humphrey Downgrades Pennsylvania Real Estate Investment Trust (PEI) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!